Cancer and Metastasis Reviews

, Volume 23, Issue 1, pp 63–75

Role of cyclooxygenase-2 in colorectal cancer


DOI: 10.1023/A:1025863029529

Cite this article as:
Sinicrope, F.A. & Gill, S. Cancer Metastasis Rev (2004) 23: 63. doi:10.1023/A:1025863029529


Cyclooxygenase-2 (COX-2) is an inducible enzyme that regulates prostaglandin synthesis and is overexpressed at sites of inflammation and in several epithelial cancers. Recently, a causal link for COX-2 in epithelial tumorigenesis was shown in genetically-manipulated animal models of colon and breast carcinoma. Data indicate that COX-2 is involved in the regulation of apoptosis, angiogenesis, and tumor cell invasiveness, which appear to contribute to its effects on tumorigenesis. Multiple studies have shown that nonselective COX and selective COX-2 inhibitors effectively prevent experimental colon cancer. Furthermore, sulindac and the selective COX-2 inhibitor celecoxib were shown to regress colorectal polyps in patients with familial adenomatous polyposis. Although the exact anti-tumor mechanisms of these agents await further study, data indicate that both COX-dependent and COX-independent mechanisms may be important. In this review, the association between COX-2 and colorectal tumorigenesis and potential mechanisms of this effect are discussed. Additionally, evidence supporting the role of NSAIDs and selective COX-2 inhibitors for the prevention and treatment of human colorectal cancer is reviewed.

cyclooxygenase-2colorectal cancerNSAIDstumorigenesiscoxibs

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  1. 1.Mayo ClinicDivision of Gastroenterology and Hepatology, Division of Medical OncologyRochester